Clinical

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.

Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.

Mirvetuximab soravtansine, particularly in combination regimens, showed promising efficacy and an acceptable safety profile in recurrent ovarian cancer.

Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.

Pigment epithelial detachment and hyperreflective foci had better early control in age-related macular degeneration (AMD) when treated with faricimab.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to prevent high-cost care episodes, emphasizing the need for predictive analytics, streamlined access, and real-world comparative data to guide treatment sequencing decisions.

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion (DM-BUP) was associated with lower total health care costs compared with other therapies, outlining strategies managed care organizations can use to promote cost-effective treatment adoption.

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in platinum-sensitive recurrent ovarian cancer.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

US adults with arthritis have higher odds of stress, urge, and mixed urinary incontinence, highlighting the need for routine screening and integrated care.

Early diagnosis and treatment are crucial for managing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, yet barriers hinder timely intervention.